Evidence map›Paper›PMID 41571613›Full record

ArticleInternational forum of allergy & rhinology2026

Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis.

Eric R Ramos, Sriram Satyavolu, Ashley L Miller, George A Scangas, Zachary M Soler, Rodney J Schlosser, Yufan Lin, Vinay K Rathi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric R RamosThe Ohio State University College of Medicine, Columbus, Ohio, USA.ORCID https://orcid.org/0009-0001-3794-027X
Sriram SatyavoluThe Ohio State University College of Medicine, Columbus, Ohio, USA.
Ashley L MillerDepartment of Otolaryngology, Nationwide Children's Hospital, Columbus, Ohio, USA.
George A ScangasDivision of Rhinology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Zachary M SolerDivision of Rhinology and Sinus Surgery, Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Rodney J SchlosserDivision of Rhinology and Sinus Surgery, Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0001-6480-0275
Yufan LinDepartment of Otolaryngology - Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
Vinay K RathiDepartment of Otolaryngology - Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

key pointsMost state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.

Indexed as

Anti-Allergic AgentsInsurance CoverageMedicaidNasal PolypsOmalizumabRhinosinusitisAntibodies, Monoclonal, HumanizedChronic DiseaseHumansUnited StatesAnti-Allergic AgentsAntibodies, Monoclonal, HumanizeddupilumabOmalizumabbiologicdupilumabEDS‐FLUMCOMedicaidmepolizumabomalizumabPreferred Drug Listprior authorizationstep therapy

Identifiers

PMID41571613
PMCPMC12951821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.